This analysis examines the historical and forecast performance for Barr in the generic pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance. An interactive data and analysis tool provides quantitative and qualitative information.
Scope
Highlights
Reasons to Purchase
Benchmark Barrs performance against key rivals in the generic pharmaceutical sector Understand the impact of the Pliva acquisition on Barrs overall performance Evaluate Barrs historical and forecast, branded and generic growth drivers and resistors
